These facts are compatible with the case of MS patients who are known to have increased CSF levels of TNF-α, IFN-γ, and IL-1β, among other inflammatory mediators (Rovaris et al., 1996; Khademi et al., 2000; Baraczka et al., 2003). Here, IFNG is linked to myeloid sarcoma.